You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALK TKI

Showing 1 - 25 of 897
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-small-cell Lung Carcinoma Trial in Beijing (SY-3505)

Recruiting
  • Non-small-cell Lung Carcinoma
  • Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
May 11, 2023

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

Recruiting
  • Non Small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 9, 2022

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

    Recruiting
    • Non-Small Cell Carcinoma of Lung, TNM Stage 4
    • +5 more
      • Aurora, Colorado
        University of Colorado, Cancer Center
      Nov 3, 2021

      Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

      Recruiting
      • Non Small Cell Lung Cancer
      • anti-PD-1 or anti-PD-L1
      • +2 more
      • Shanghai, China
        Oncology Department, Shanghai Chest Hospital
      Jul 26, 2022

      Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

      Recruiting
      • Carcinoma
      • Non-Small-Cell Lung
      • Orange, California
      • +31 more
      Dec 6, 2022

      Plasma NGS for Assessment, Characterization, Evaluation of ALK

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Plasma Next Generation Sequencing (NGS)
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      Jan 26, 2023

      NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

      Terminated
      • Non-small Cell Lung Cancer
      • Davis, California
      • +1 more
      Dec 22, 2022

      NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

      Recruiting
      • NSCLC
      • Berlin, Germany
      • +25 more
      Nov 10, 2022

      Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

      Recruiting
      • Locally Advanced Solid Tumor
      • Metastatic Solid Tumor
      • Orange, California
      • +13 more
      Jan 31, 2023

      NSCLC Trial in United States (brigatinib)

      Terminated
      Has Results
      • Non-Small Cell Lung Cancer
      • Denver, Colorado
      • +3 more
      Jan 10, 2023

      NSCLC Trial in Beijing (SY-3505)

      Recruiting
      • Non-small Cell Lung Cancer
      • Beijing, Beijing, China
        Cancer Hospital, Chinese Academy of Medical Sciences
      Mar 17, 2022

      ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Pure

      Completed
      • Non-small Cell Lung Cancer
      • Changsha, Hunan, China
        Hunan Cancer Hospital
      Sep 23, 2021

      Non Small Cell Lung Cancer, NSCLC, NSCLC Trial in Australia, Korea, Republic of, United States (TPX-0131)

      Active, not recruiting
      • Non Small Cell Lung Cancer
      • +5 more
      • Orange, California
      • +13 more
      Nov 7, 2022

      Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)

      Recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • Middletown, New Jersey
      • +5 more
      Aug 17, 2023

      Non Small Cell Lung Cancer Trial in Beijing (Ensartinib)

      Recruiting
      • Non Small Cell Lung Cancer
      • Beijing, Beijing, China
      • +1 more
      Aug 17, 2022

      Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

      Active, not recruiting
      • Non-Small-Cell Lung Carcinoma
      • New York, New York
        Pfizer Inc
      Apr 12, 2022

      Brain Metastases, Lung Cancer Trial in Duarte, Aurora, Rochester (Brigatinib)

      Active, not recruiting
      • Brain Metastases
      • Lung Cancer
      • Duarte, California
      • +2 more
      Feb 8, 2022

      A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib

      Recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • +4 more
        • Guangzhou, Guangdong, China
          Cancer Center, Sun Yat-sen University
        Oct 25, 2022

        Ensatinib in alK-positive Patients Undergoing Initial Treatment

        Recruiting
        • ALK Positive
        • +2 more
        • Beijing, Beijing, China
          Beijing Cancer Hospital
        Nov 16, 2021

        Lung Cancer, EGFR Gene Mutation, EGFR Trial in Charlottesville (Sensus Smartwatch Application, RX Cap, Fitbit Sense)

        Recruiting
        • Lung Cancer
        • +3 more
        • Sensus Smartwatch Application
        • +3 more
        • Charlottesville, Virginia
          University of Virginia
        Aug 26, 2022

        Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

        Recruiting
        • Locally Advanced Solid Tumors
        • +3 more
        • Oral repotrectinib (TPX-0005)
        • Los Angeles, California
        • +27 more
        Aug 9, 2022

        Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

        Withdrawn
        • Non-Small Cell Lung Cancer
        • InVisionFirst-Lung ctDNA assay
        • Los Angeles, California
        • +2 more
        Sep 16, 2022

        NSCLC Trial in Worldwide (X-396 (ensartinib), crizotinib)

        Active, not recruiting
        • Non-small Cell Lung Cancer
        • Phoenix, Arizona
        • +122 more
        Oct 21, 2022